R3 Stem Cell is a global provider of regenerative medicine services designed to harness the human body’s repair mechanisms to restore damaged tissues and alleviate pain without surgery. In over ten years, R3 has delivered more than 16,000 stem cell procedures across forty-five centers worldwide, giving patients back the freedom of painless and unimpeded movement. As a B2B and B2C firm, R3 supplies practices and patients alike with education on regenerative therapy, sharing the results of decades of research to revolutionize pain relief treatments. Founder David Greene MD, MBA, tells us more.
Specialists in regenerative therapies, R3 Stem Cell has grown in little over a decade to become a global network of centers that provides stem cell procedures and therapies designed to assist the body in healing itself from musculoskeletal, neurological, autoimmune conditions and more. Whilst most existing pain management procedures are effective in suppressing the pain by removing the sense of discomfort, regenerative therapy is unique in its ability to provide relief by dealing directly with the cause of pain.
Founded over ten years ago by David Greene, MD MBA, R3 was created with the aim of allowing patients to decrease pain and improve functional ability with affordable, non-intrusive procedures. This mission has been the driving force in R3’s leading scientific body of IRB approved research into regenerative medicine and the firm’s international expansion to almost fifty centers across the globe. All R3 centers strictly adhere to the same uncompromising principles upon which David built his firm: patient safety is paramount; stem cell biologic quality is uncompromising; aim to be the market leader in provider and patient education with accurate information; patient outcomes continue to guide our Best Practice treatment protocols; and treatments are cost effective using our volume to leverage savings for patients. As R3 grows across the US and internationally, its commitment to these values is unwavering.
“Our client base is actually on two levels,” David tells us, “B2B and B2C. So, we have to approach them differently. For the B2C aspect, it’s important to provide significant education in language that patients can understand and is also relevant to helping in the decision-making process. Patients come into regenerative medicine at all different knowledge levels, so we try to meet everyone’s needs. This has been achieved by such assets as our Stem Cell Master Class, which is free and teaches patients all about regenerative therapies.
“From a B2B perspective, our goal is to assist practices with whatever tools they need for success. This may include regenerative patient marketing, provider training and first-rate biologics. Over the years we have added hands on provider training with real patients for MSK, IV and aesthetics. No one else does this.”
R3 is also a leader of clinical research into regenerative medicine and is the only US company to have achieved Institutional Review Board Approval for the investigation of regenerative therapies with amniotic and umbilical cord tissue for several condition categories. Using patients’ own tissue elements such as blood, adipose or bone marrow, or amniotic fluid or umbilical cord tissue collected from consenting donors after scheduled C-sections, regenerative therapies have eliminated ethical concerns surrounding fetal involvement, thus propelling the alternative pain relief treatment closer to the mainstream.
Patients of R3 Centers are therefore able to choose from a selection of procedure options to help in the regenerative processes for tendonitis, tendinosis, ligament injury, and extremity and spinal arthritis treatment. Stem cell injections derived from bone marrow or fat, amniotic-derived injections processed at an FDA regulated laboratory, Platelet Rich Plasma Therapy, and Umbilical Cord Tissue with growth factors, exosomes, cytokines and stem cells are all available as same-day outpatient therapies. All of the injections are carried out by highly skilled and caring providers and injected either into joints or soft tissues.
Whilst many clinics have also begun to branch into regenerative procedures, few have the same knowledge of best treatment protocols that R3 has developed over the past decade. Its unparalleled expertise and hassle-free treatments coupled with its lowered consumer costs has further established R3 as a premier choice for their patients and affiliated clinics. Moreover, across R3’s worldwide clinics, the team is united in its belief in the life-changing power of regenerative therapies, which translates into inimitable patient care and first-rate customer service.
As such, the recruitment process for R3 is meticulous in ensuring that candidates have the same passion for working alongside likeminded individuals to improve and save lives. “If I have an individual who isn’t willing to reach out for help in times of need or to offer help when others need it, then it’s not a good fit,” says David. “Our team truly likes and respects each other and believes in regenerative therapies!” Close collaboration, mutual respect, and a commitment to regenerative medicines has been instrumental in the successful international growth of R3 over the years.
A great deal of this growth has been seen outside of the US, with the benefits of regenerative therapies rooted in stem cells and exosomes being recognized around the world. “As the market leader, I feel like it is our responsibility to bring these therapies to those who need it, in a way that is safe and effective,” says David. Whilst clinical effectivity remains the priority, David and his team are also able to leverage the volume of procedures carried out to make their treatments cost-effective too.
Thus, as R3 heads into 2021, it is with great excitement about a future of promising yet judicious growth. As such, the firm will maintain its quality assurance standards so that patient safety remains paramount, whilst at the same time expanding its international footprint to provide its therapies to even more patients. In addition, as research continues to bring to light the capabilities of stem cell regeneration, R3 is hoping to use its therapies to treat an even greater selection of conditions aside from musculoskeletal, anti-aging, neurologic, autoimmune, cosmetic, organ failure and the many others that are so far treatable through regenerative therapy. Thus, it is an exciting time for R3 as it shapes a promising new future in treatments for pain relief, giving patients across the world ability to take back their freedom of painless movement.
For more information, please contact David Greene at www.r3stemcell.com